We are live on ! Find out more
IC

Ikarian Capital Portfolio holdings

AUM $928M
1-Year Est. Return 596.14%
This Fund
S&P 500
This Quarter Est. Return
+39.15%
1 Year Est. Return
+596.14%
3 Year Est. Return
+5,184.12%
5 Year Est. Return
+18,295.93%
10 Year Est. Return
–
AUM
$831M
AUM Growth
+$203M
Cap. Flow
+$8.44M
Cap. Flow %
1.02%
Top 10 Hldgs %
41.06%
Holding
181
New
59
Increased
25
Reduced
46
Closed
41

Top Buys

Rank Stock Value
1
RCKT icon
Rocket Pharmaceuticals
RCKT
+$11.9M
2
AKRO
Akero Therapeutics
AKRO
+$9.31M
3
TARS icon
Tarsus Pharmaceuticals
TARS
+$9.18M
4
CPRX
Catalyst Pharmaceutical
CPRX
+$6.77M
5
IMVT icon
Immunovant
IMVT
+$6.73M

Top Sells

Rank Stock Value
1
MRK icon
Merck
MRK
+$11.5M
2
INSM icon
Insmed
INSM
+$7.55M
3
IDYA icon
IDEAYA Biosciences
IDYA
+$6.95M
4
BHVN icon
Biohaven
BHVN
+$6.68M
5
BMEA icon
Biomea Fusion
BMEA
+$6.06M

Sector Composition

Rank Sector Weight
1 Miscellaneous 67.6%
2 Healthcare 32.4%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
SPY icon
1
PUT
State Street SPDR S&P 500 ETF Trust
SPY
$814B
$64.1M 7.71%
+1,500
New +$667K
SRPT icon
2
PUT
Sarepta Therapeutics
SRPT
$2.38B
$44.5M 5.36%
3,673
-118,427
-97% -$13.4M
QQQ icon
3
PUT
Invesco QQQ Trust
QQQ
$490B
$43M 5.17%
+1,200
New +$445K
XBI icon
4
PUT
State Street SPDR S&P Biotech ETF
XBI
$11.4B
$36.5M 4.39%
+5,000
New +$399K
SLRN
5
DELISTED
ACELYRIN
SLRN
$29.7M 3.57%
2,918,426
– –
IMVT icon
6
CALL
Immunovant
IMVT
$8.11B
$27.8M 3.34%
7,230
-318,970
-98% -$7.21M
SRPT icon
7
CALL
Sarepta Therapeutics
SRPT
$2.38B
$25.7M 3.1%
2,123
-19,977
-90% -$2.26M
MRNA icon
8
PUT
Moderna
MRNA
$58.1B
$25.2M 3.04%
+2,443
New +$273K
CRNX
9
DELISTED
Crinetics Pharmaceuticals
CRNX
$23.6M 2.84%
792,920
+317,920
+67% +$6.55M
IMVT icon
10
PUT
Immunovant
IMVT
$8.11B
$21.2M 2.56%
5,534
-70,466
-93% -$1.59M
ABBV icon
11
CALL
AbbVie
ABBV
$453B
$19.8M 2.38%
+1,325
New +$195K
SLNO
12
DELISTED
Soleno Therapeutics
SLNO
$15.8M 1.91%
+536,720
New +$3.25M
AKRO
13
PUT
DELISTED
Akero Therapeutics
AKRO
$15.4M 1.86%
+3,049
New +$142K
CRNX
14
PUT
DELISTED
Crinetics Pharmaceuticals
CRNX
$13.5M 1.63%
+4,543
New +$93.6K
RCKT icon
15
Rocket Pharmaceuticals
RCKT
$424M
$13.4M 1.61%
+654,726
New +$11.9M
NUVL
16
DELISTED
Nuvalent
NUVL
$12.8M 1.54%
278,034
+5,282
+2% +$234K
BBIO icon
17
BridgeBio Pharma
BBIO
$14.6B
$12.5M 1.5%
473,126
+43,440
+10% +$1.23M
CRNX
18
CALL
DELISTED
Crinetics Pharmaceuticals
CRNX
$12.1M 1.45%
+4,054
New +$83.5K
IMVT icon
19
Immunovant
IMVT
$8.11B
$11.4M 1.38%
+297,794
New +$6.73M
NUVL
20
CALL
DELISTED
Nuvalent
NUVL
$11M 1.32%
2,395
-2,005
-46% -$89K
SNDX icon
21
PUT
Syndax Pharmaceuticals
SNDX
$1.84B
$10.9M 1.31%
+7,500
New +$142K
AKRO
22
DELISTED
Akero Therapeutics
AKRO
$10.1M 1.22%
+200,000
New +$9.31M
AKRO
23
CALL
DELISTED
Akero Therapeutics
AKRO
$10.1M 1.21%
+1,989
New +$92.6K
KRYS icon
24
PUT
Krystal Biotech
KRYS
$10.6B
$9.8M 1.18%
845
-9,455
-92% -$1.15M
REPL icon
25
PUT
Replimune Group
REPL
$1.42B
$9.3M 1.12%
5,438
-342,762
-98% -$6.73M
1
2 3 4 5

Similar funds

CAM
Claret Asset Management Montreal, Quebec, Canada $928M AUM 25.4% 1-Year Est. Return
FSA
Fort Sheridan Advisors Highland Park, Illinois $928M AUM 38.18% 1-Year Est. Return
RCM
Redwood Capital Management New York $927M AUM 153.64% 1-Year Est. Return
CICI
Capital Investment Counsel Inc Raleigh, North Carolina $929M AUM 53.07% 1-Year Est. Return
AWM
Arista Wealth Management Las Vegas, Nevada $927M AUM 24.58% 1-Year Est. Return
CB
Community Bank Dewitt, New York $926M AUM 31.78% 1-Year Est. Return
AA
ABC Arbitrage Paris, France $926M AUM 45.9% 1-Year Est. Return
MPM
MBB Public Markets Chicago, Illinois $926M AUM 11.38% 1-Year Est. Return

Ikarian Capital's Q3 2023 Portfolio in Review

As of Q3 2023, Ikarian Capital held 181 positions worth $831M, up 32% from $628M the previous quarter. Its ten largest holdings account for 41% of the portfolio.

Ikarian Capital's Q3 2023 filing shows 59 new, 25 increased, 46 reduced and 41 closed positions. Its largest new stake was Rocket Pharmaceuticals: 654,726 shares worth $13.4M. The largest sale was Merck, an estimated $11.5M.

By sector, the portfolio is most concentrated in Miscellaneous at 68% of assets, up from 55% a quarter earlier, followed by Healthcare.

  • Ikarian Capital's largest Q3 2023 buy was Rocket Pharmaceuticals: 654,726 shares worth $13.4M.
  • Ikarian Capital added most to Crinetics Pharmaceuticals in Q3 2023, an estimated $6.55M increase.
  • Ikarian Capital's biggest Q3 2023 reduction was Insmed, cutting an estimated $7.55M.
  • Ikarian Capital fully exited Merck in Q3 2023, selling an estimated $11.5M.
  • Ikarian Capital's ten largest holdings make up 41% of its $831M portfolio in Q3 2023.
  • Ikarian Capital opened 59 new positions and closed 41 in Q3 2023.
  • Ikarian Capital's portfolio value rose 32% quarter-over-quarter to $831M.

Based on Ikarian Capital's 13F filing for Q3 2023, filed 14 Nov 2023.